BioSyent (RX.V or BIOYF) is a rapidly growing pharmaceutical company that acquires or in-licenses proven drugs and markets them in Canada. Their business model is to build and sell a portfolio of products that have a peak penetration potential that is too small for major pharmaceutical companies. What has fascinated us about BioSyent is their ability to consistently grow revenue and earnings. In fact, their pharmaceutical sales have grown sequentially for the past 12 quarters, which is very rare in the microcap space. In 2012 they announced several new products that they have added to their portfolio plus they have a nice pipeline of additional products that we expect to further fuel their growth. In the most recent quarter they grew revenues 60% and net income 79% year/year. Listen to CEO Rene Goehrum as he tells the story.

1. 1

2. Disclaimer
This presentation is for informational purposes only and should not be considered
as an offer to buy or sell securities. No stock exchange has either approved or
disapproved of the information that is contained in this presentation. This
presentation may contain forward-looking statements within the meaning of
Canadian Securities legislation and the forward-looking statements contained
herein are made as at the date of this presentation and, accordingly, are subject to
change after such date. Undue reliance should not be placed on such statements.
These statements involve a number of risks and uncertainties including statements
regarding the outlook for BioSyent Inc., business and operational results.
By nature, these risks and uncertainties could cause actual results to differ
materially from what has been indicated. Factors that could cause actual results to
differ materially from any forward-looking statement include, but are not limited to,
failure to obtain governmental regulatory approvals, product recalls, competition
from similar products and other factors including those risks and uncertainties
identified above.
BioSyent Inc. undertakes no obligation to update publicly or otherwise revise any
forward-looking information as a result of new information, future results or other
such factors which affect this information, except as required by law.
2

3. BioSyent is a profitable, growth oriented Specialty
Pharmaceutical company that sources and markets innovative
products that improve the lives of patients and support the
healthcare professionals that treat them.
Today’s presentation by:
René C. Goehrum
Chairman, President & CEO of BioSyent Inc.
3

4. About BioSyent
Listed on the Toronto Venture Exchange, under the trading Symbol “RX,” U.S.
OTC “BIOYF”, BioSyent searches the globe to identify and acquire exclusive
rights to pharmaceutical products that have been successfully developed and
proven to be safe and effective. Once a product of interest has been found,
BioSyent then acquires the exclusive rights and manages these products
through the Canadian regulatory process (approval); and once approved,
markets these products throughout Canada.
Selected from over 2,200 listed companies, BioSyent was named as one of the
2012 TSX Venture Top 50 and was ranked #5 in the TSX Venture’s Life
Sciences and Technology group.
4

5. Investment Highlights
1. Proven business model with 2 marketed pharmaceutical
products; 1 product approved in preparation for 2013
launch; 2 products being prepared for Health Canada
filing.
2. High growth – during the period January 1, 2010
through September 30, 2012, revenue has grown at an
annualized compound growth rate of 69%.
3. Demonstrated profitability – 9 month 2012 basic EPS of
$0.08; FY2011 basic EPS $0.03; FY2010 basic EPS
$0.004.
4. No debt and an unutilized operating line of credit (Royal
Bank of Canada).
5

6. Investment Highlights
5. Strong Balance Sheet to fund continued growth – cash
and cash equivalents of $1.94 million as of September
30, 2012, representing YTD growth of 83% (+$0.88
million) over previous year-end.
6. Clean capital structure – 13,271,195 shares currently
issued and outstanding. No warrants outstanding.
1,205,000 options outstanding. Total diluted shares:
14,476,195.
7. Active in-licensing (new product) funnel.
8. Experienced management team.
6

7. Strategy
1. Expansion of our product base by in-licensing exclusive Canadian rights to
proven pharmaceutical products that address unmet medical needs.
2. Manage technology risk by focusing on already commercialized products,
not yet available in Canada.
3. Minimize deal competition by focusing on niche products with a peak
penetration potential of $2-15 million – below threshold of mid-size and
larger pharma companies.
4. BioSyent builds its sales and marketing teams around a product. This
approach maximizes profit and minimizes costs, as sales teams are put in
place only when needed and expand only when the product’s sales can
support the expansion.
7

8. Capabilities
1. Commercialization excellence in the 9th largest global
pharmaceutical market (IMS).
2. Regulatory Approval, QA-QC, Compliance.
3. Bilingual (English/French) operations, sales and customer service.
4. Canada-wide sales, marketing team.
5. Hospital, wholesaler and retail pharmacy distribution network.
6. Group hospital purchasing relationships (existing contracts).
7. All required drug licenses.
8. Medical/Drug information support.
9. Formulary and reimbursement management.
8

9. Sales Team
1. 10 medical sales representatives with an average of 20 years in
Pharma.
2. Broad experience base (Specialty, Hospital and GP) in a wide
variety of therapeutic classes.
3. Proximity to all major cities/population centers.
4. All markets including virtual territories supported by e-details, web,
direct mail, video conferencing, sampling programs.
5. We build teams to fit new product opportunities/needs.
9

10. Recent Corporate Events
Time Period Event
FY 2010 FY sales +63% , add 3 medical reps
July 2011 Health Canada approval of Cathejell ™
primary use in hospitals
FY 2011 FY sales +67%, add 3 medical reps
February 2012 BioSyent named to the TSX TOP 50 Ranking
Moved to new corporate head office
July 2012 Health Canada approval of FeraMAX® Powder.
1st new oral iron product for Canadian children in 50 years
August 2012 Sign exclusive licensing and distribution agreement
for 2 new drugs (patented)
September 2012 Sales team reaches 10 medical reps
September 2012 YTD September 30 sales reach $3.7 Million (+76%), Net Income grows 196%
Q1 2013 Planned FeraMAX® Powder product launch
Q1 2013 Planned 2 new products filed at Health Canada
10

11. 11

12. Our Products | FeraMAX® 150
1. Approved by Health Canada for the
treatment of iron deficient anaemia
– therapeutic dose.
2. Distributed across Canada, broadly
available via ~ 8,000 pharmacies
including majors such as Shoppers
Drug Mart, Rexall, Jean Coutu, Wal-
Mart, Costco, Loblaw.
3. Clinically proven and effective. Well
tolerated, with an improved side-
effect profile.
4. Brand owned by BioSyent.
Exclusive supply deal.
12

13. Our Products | FeraMAX® Powder
1. Approved by Health Canada for
prevention of iron deficiency.
2. Extension of the FeraMAX® brand
– based upon the same
compound as FeraMAX® 150.
3. Developed in response to
requests by Paediatricians and
GPs that treat children.
4. Gentle on GI tract - reduced side
effects.
5. Pleasant taste improves
compliance.
13

14. Our Products | CATHEJELL™ Jelly 2%
1. Approved by Health Canada.
Proven safe and effective with 40
year track record in 54 countries.
2. Used as a Sterile Topical Anesthetic
- primarily in cystoscopies.
3. Unique collapsible accordion
syringe with trauma free applicator
tip.
4. Single handed application, no
syringe assembly required.
5. No restrictions of use in the
hospital.
14

15. COMPANY FINANCIAL INFORMATION
15

16. Pharmaceutical Products Sales By Quarter
1,180,717
1,200,000
1,054,026
1,000,000
761,372
800,000
657,442
604,523
C$
600,000
465,163
400,000 322,648
247,941
191,716
155,024
200,000
81,237
-
16 Quarter
16

17. Revenue Growth 9 Months
(YTD Sept)
$3,696,201
$4,000,000
$3,500,000
$2,808,666
$3,000,000
$2,500,000
CAD$2,000,000 $1,681,210
$1,500,000 $1,101,991
1,029,902
$1,000,000
$500,000
$0
2008 2009 2010 2011 2012
Period
17

18. Total Comprehensive Income
9 Months
(YTD Sept)
1,200,000 $1,034,828
1,000,000
800,000
600,000
$417,950
CAD 400,000
200,000 $48,386
-
(200,000)
(287,892) (260,556)
(400,000)
2008 2009 2010 2011 2012
Period
18

19. Cash Flow
9 Months
(YTD Sept)
1,000,000 878,751
800,000
586,951
600,000
400,000
CAD
200,000 40,307
-
(200,000)
(295,260)
(351,725)
(400,000)
2008 2009 2010 2011 2012
Period
19
19

20. Share Ownership by Management &
Directors
20

21. 21

22. Management
René C. Goehrum | President & CEO
• 30+ years spanning start-up, early stage, growth and mature businesses;
• Prior operating and services experience: Procter & Gamble, Sandoz (now
Novartis), Boehringer Ingelheim and others;
• Functional experience: Leadership, strategy, business development,
operations, corporate finance, sales, marketing.
Alfred D'Souza | Vice-President & Chief Financial Officer
• Colgate Palmolive and Unilever in finance, accounting, mergers,
acquisitions. Last position before BioSyent - Finance Director Colgate
Palmolive India (USD $225 million). Start-up leadership team, Colgate
Vietnam, grew to $25 million.
22

23. Management
Kevin Wilson | Vice President of Sales and Marketing
• 20+ years experience in pharmaceutical sales, sales leadership, and
marketing at Abbott, Bayer, Pharmacia/Searle (now Pfizer);
• Director of Marketing on three different therapeutic classes.
Tom Carson | Director of Business Development
• 30+ years pharmaceutical experience in sales, product management,
marketing, sales information and business development;
• Prior experience: DuPont Pharma, Bristol Myers Squibb.
23

24. Directors
René C. Goehrum | Chairman
Douglas R. Larson | Director
Douglas Larson has considerable leadership and governance experience.
Before August 1995, he served as President and CEO of James Richardson
and Sons Ltd.- Grain Division, Canada’s largest privately owned grain company
with sales in excess of $100 million and over 1200 employees.
Peter Lockhard | Non-Executive Director
Mr. Lockhard has extensive senior management experience with successful
high-growth companies in the IT and marketing services industries, including
VP Professional Services of Flo Network, a permission-based e-messaging
service provider (acquired by DoubleClick). Mr. Lockhard currently serves as
the Chief Operating Officer of Points International Ltd. a $125 million revenue
company listed on Nasdaq and the TSX (Nasdaq:PCOM; TSX:PTS).
24

25. Directors
Milton E. Wakefield | Non-Executive Director
Milton Wakefield completed a ten-year term as Commissioner of the Canadian
Grain Commission, the last seven as its Chief Commissioner, in 1997. This
organization had over 800 employees and an Operating Budget of $55 million. He
also served eight years in the Legislative Assembly of the Province of
Saskatchewan. Mr. Wakefield is currently the Chairman of the Board of Lakeland
College in Alberta, an institution with over 8,000 students and an Operating Budget
of over $65 million.
Paul R. Montador | Non-Executive Director
Mr. Montador has over 35 years of experience in healthcare product sales,
marketing, leadership, and corporate governance. At present, he is the CEO
(founder) of InspiAir Inc. and Chairman of the Board of ThinkFirst/Pensez d’Abord
Canada, a national non-profit organization dedicated to the prevention of brain and
spinal cord injuries. Mr. Montador’s roles have also included CEO of SciCan Inc.,
President of Johnson & Johnson Medical Products (Canada), President and Board
member of Amsco Inc., General Manager of American Hospital Supply (Canada),
and Board member of CryoCath Technologies Inc. (acquired by Medtronic Inc.).
25

26. Stock Information
February 5, 2013
Exchange & Trading Symbol: TSXV: RX
52 Week Hi / Low: $1.40 / $0.41
Current Shares: 13,271,195
Warrants: 0
Options: 1,205,000
Fully Diluted: 14,476,195
P/E Ratio: 13.80
P/B Ratio: 5.89
BioSyent has experienced strong stock performance over the last year with no
need to access debt or equity financing.
26

27. Contact Information
Investors:
René Goehrum
President and CEO
(905) 206-0013 ext.320
rgoerhum@biosyent.com
Business Development:
Tom Carson
Director of Business Development
(905) 206-0013 ext.309
tcarson@biosyent.com
Address:
170 Attwell Drive, Suite 520
Toronto, Ontario, Canada M9W 5Z5
27

28. 28